FIERCELY FOCUSED
ON SOLUTIONS

OUR Publications

We welcome you to explore our comprehensive publications database. All publications are available to download. Please select one or more fields from the list below to help narrow your search.

Date Title Lead Author Drug Conference Download
November 04 2020 Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 UNITY-CLL Study Gribben J, et al. umbralisib + ublituximab (U2), ublituximab (TG-1101), umbralisib (TGR-1202), ublituximab (TG-1101) American Society of Hematology Annual Meeting (ASH) Download
November 04 2020 Umbralisib, the Once Daily Dual Inhibitor of PI3Kδ and Casein Kinase-1ε Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global UNITY-NHL Trial Zinzani P, et al. umbralisib (TGR-1202) American Society of Hematology Annual Meeting (ASH) Download
November 04 2020 A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax (U2-Ven) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Barr P, et al. umbralisib (TGR-1202), umbralisib + ublituximab (U2), ublituximab (TG-1101), umbralisib (TGR-1202), ublituximab (TG-1101) American Society of Hematology Annual Meeting (ASH) Download
November 04 2020 Clinical Activity of TG-1701, As Monotherapy and in Combination with Ublituximab and Umbralisib (U2), in Patients with B-Cell Malignancies Cheah C, et al. TG-1701, ublituximab (TG-1101), umbralisib (TGR-1202), TG-1701 American Society of Hematology Annual Meeting (ASH) Download
July 08 2020 The Dual PI3Kδ/CK1ε Inhibitor Umbralisib Exhibits Unique Immunomodulatory Effects on CLL T Cells Pinilla-Ibarz J. et al. umbralisib (TGR-1202) Blood Advances Journal - published by The American Society of Hematology Donwload
June 22 2020 TG-1701, a Novel Irreversible Bruton’s Kinase (BTK) Inhibitor, Cooperates with Ublituximab-Driven ADCC and ADCP in In Vitro and In Vivo Models of Ibrutinib-Resistant Mantle Cell Lymphoma Ribeiro M, et al. ublituximab (TG-1101), TG-1701, ublituximab (TG-1101), TG-1701 American Association for Cancer Research Annual Meeting (AACR) Download
June 12 2020 Long term Results of a Phase I/ Ib Study of Ibrutinib in Combination with Umbralisib in Patients with Relapsed/Refractory CLL or MCL Davids M, et al. umbralisib (TGR-1202) Congress of the European Hematology Association (EHA) Download
June 12 2020 Safety and Activity of the Once Daily Selective Bruton Tyrosine Kinase (BTK) Inhibitor TG-1701 in Patients with Chronic Lymphocytic Leukemia (CLL) and Lymphoma Cheah C, et al. TG-1701 Congress of the European Hematology Association (EHA) Download
May 29 2020 Effect of Adding Ublituximab to Ibrutinib on PFS, ORR, and MRD Negativity in Previously Treated High-Risk Chronic Lymphocytic Leukemia: Final Results of the GENUINE Phase III Study Sharman J, et al. ublituximab (TG-1101) American Society of Clinical Oncology Annual Meeting (ASCO) Download
April 30 2020 A Phase 2 Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis Fox E, et al. ublituximab (TG-1101) Multiple Sclerosis Journal Download
February 27 2020 Long-term Follow-up Results From the Phase 2 Multicenter Study of Ublituximab(UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients With Relapsing Multiple Sclerosis (RMS) Fox E, et al. ublituximab (TG-1101) Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Download
December 09 2019 Phase 1 Study of TG-1701, a Selective Irreversible Inhibitor of Bruton’s Tyrosine Kinase (BTK), in Patients with Relapsed/Refractory B-Cell Malignancies Cheah C, et al. umbralisib (TGR-1202), ublituximab (TG-1101), TG-1701, ublituximab (TG-1101), umbralisib (TGR-1202), TG-1701 American Society of Hematology Annual Meeting (ASH) Download
December 08 2019 A Phase 1/2 Study of Umbralisib, Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). Barr P, et al. umbralisib (TGR-1202), ublituximab (TG-1101), umbralisib (TGR-1202), ublituximab (TG-1101) American Society of Hematology Annual Meeting (ASH) Download
November 21 2019 Ublituximab and Umbralisib in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Lunning M, et al. umbralisib (TGR-1202), ublituximab (TG-1101), umbralisib (TGR-1202), ublituximab (TG-1101) Blood Medical Journal - published by the American Society of Hematology (Blood) Download
September 23 2019 A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib in Patients with Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant to Prior BTK or PI3K Delta Inhibitor Therapy Mato A, et al. umbralisib (TGR-1202) International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Download
September 23 2019 Phase I/II Triple Therapy Study of Umbralisib and Ublituximab (U2) Combined with Checkpoint Inhibition in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Richter’s Transformation (RT) Mato A, et al. umbralisib (TGR-1202), ublituximab (TG-1101), umbralisib (TGR-1202), ublituximab (TG-1101) International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Download
September 12 2019 Long-term Follow-up Results from the Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Multiple Sclerosis (RMS) Fox E, et al. ublituximab (TG-1101) European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Download
September 12 2019 Study Design and Patient Demographics of the ULTIMATE Phase III Trials Evaluating Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Multiple Sclerosis (RMS) Cree B, et al. ublituximab (TG-1101) European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Download
July 12 2019 Open Label Extension (OLE) of Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis (RMS) Fox E, et al. ublituximab (TG-1101) 5th Congress of the European Academy of Neurology (EAN) Download
June 20 2019 Phase I/II Study of Umbralisib (TGR-1202) in Combination with Ublituximab (TG-1101) and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter’s Transformation Mato A, et al. umbralisib (TGR-1202), ublituximab (TG-1101), umbralisib (TGR-1202), ublituximab (TG-1101) International Congress on Malignant Lymphoma (ICML) Download
June 20 2019 A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib in Patients with Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant to Prior BTK or PI3K Delta Inhibitor Therapy Mato A, et al. umbralisib (TGR-1202) International Congress on Malignant Lymphoma (ICML) Download
June 19 2019 Umbralisib Monotherapy Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Registration Directed Phase 2 Study Zinzani P, et al. umbralisib (TGR-1202) International Congress on Malignant Lymphoma (ICML) Download
June 14 2019 The Novel Bispecific CD47-CD19 Antibody TG-1801 Potentiates the Activity of Ublituximab-Umbralisib (U2) Drug Combination in Preclinical Models of B-NHL Ribeiro M et al. TG-1801 Congress of the European Hematology Association (EHA) Download
June 09 2019 The Novel Bispecific CD47-CD19 Antibody TG-1801 Potentiates the Activity of Ublituximab-Umbralisib (U2) Drug Combination in Preclinical Models of B-NHL Ribeiro M et al. umbralisib (TGR-1202), ublituximab (TG-1101), TG-1801, ublituximab (TG-1101), umbralisib (TGR-1202), TG-1801 International Congress on Malignant Lymphoma (ICML) Download
June 04 2019 Umbralisib Monotherapy Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-label, Registration Directed Phase 2 Study Fowler N, et al. umbralisib (TGR-1202) American Society of Clinical Oncology Annual Meeting (ASCO) Download
May 07 2019 Open Label Extension (OLE) of a Phase 2 Multicenter Study Of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis (RMS) Fox E, et al. ublituximab (TG-1101) American Academy of Neurology Annual Meeting (AAN) Download
May 03 2019 B cell Depletion with Ublituximab Reshapes the T Cell Profile in Multiple Sclerosis Patients Lovett-Racke A, et al. ublituximab (TG-1101) Journal of Neuroimmunology Download
April 01 2019 TG Therapeutics Reports Positive Interim Data from UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Marginal Zone Lymphoma at the 2019 AACR Annual Meeting Fowler N, et al. umbralisib (TGR-1202) American Association for Cancer Research Annual Meeting (AACR) Download
February 28 2019 Final Results of a Phase 2 Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients with Relapsing Forms of Multiple Sclerosis (RMS) Fox E, et al. ublituximab (TG-1101) Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Download
February 01 2019 Tolerability and Activity of Ublituximab, Umbralisib, and Ibrutinib in Patients with Chronic Lymphocytic Leukaemia and Non-Hodgkin Lymphoma: A Phase 1 Dose Escalation and Expansion Trial Nastoupil L, et al. umbralisib (TGR-1202), ublituximab (TG-1101), umbralisib (TGR-1202), ublituximab (TG-1101) THE LANCET Haematology Download
December 14 2018 Umbralisib in Combination with Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukaemia or Mantle Cell Lymphoma: A Multicentre Phase 1–1b Study Davids M, et al. umbralisib (TGR-1202) THE LANCET Haematology Download
December 03 2018 Combination of Umbralisib, Ublituximab, and Bendamustine is Safe and Highly Active in Patients with Advanced DLBCL and Follicular Lymphoma Lunning M, et al. umbralisib (TGR-1202), ublituximab (TG-1101), umbralisib (TGR-1202), ublituximab (TG-1101) American Society of Hematology Annual Meeting (ASH) Download
December 02 2018 Phase I/II Study of Umbralisib (TGR-1202) in Combination with Ublituximab (TG-1101) and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter’s Transformation Mato A, et al. umbralisib (TGR-1202), ublituximab (TG-1101), umbralisib (TGR-1202), ublituximab (TG-1101) American Society of Hematology Annual Meeting (ASH) Download
October 11 2018 Final Results of a Placebo Controlled, Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis (RMS) Fox E, et al. ublituximab (TG-1101) European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Download
June 18 2018 Phase 2 Multicenter Study Results of Ublituximab, a Novel Glycoengineered AntiCD20 Monoclonal Antibody (mAb), in Patients with Relapsing Multiple Sclerosis (RMS) Fox E, et al. ublituximab (TG-1101) 5th Congress of the European Academy of Neurology (EAN) Download
June 16 2018 Resurrecting response to ruxolitinib: A Phase I study of ruxolitinib and umbralisib (TGR-1202) in ruxolitinib-experienced myelofibrosis Moyo et al. umbralisib (TGR-1202) Congress of the European Hematology Association (EHA) Download
June 16 2018 A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib (TGR-1202) in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K Delta Inhibitor Therapy Mato A, et al. umbralisib (TGR-1202) Congress of the European Hematology Association (EHA) Download
June 15 2018 Long Term Integrated Safety Analysis Of Umbralisib (TGR-1202), A PI3K?/Ck1? Inhibitor With A Differentiated Safety Profile, In Patients With Relapsed/Refractory Lymphoid Malignancies Davids M, et. al. umbralisib (TGR-1202) Congress of the European Hematology Association (EHA) Download
June 15 2018 TG-1701 is a novel, orally available and covalently bound BTK inhibitor Normant, E et al. TG-1701 Congress of the European Hematology Association (EHA) Download
June 04 2018 A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib (TGR-1202) in Patients with CLL who are Intolerant to Prior BTK or PI3K Inhibitor Therapy Mato A, et al. umbralisib (TGR-1202) American Society of Clinical Oncology Annual Meeting (ASCO) Download
April 24 2018 Final MRI Results at 6 Months from a Phase 2 Multicenter Study of Ublituximab, A Novel Glyocoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis (RMS), Demonstrates Complete Elimination of Gd-Enhancing Lesions Inglese M, et al. ublituximab (TG-1101) American Academy of Neurology Annual Meeting (AAN) Download
April 18 2018 TG-1601 is a Novel BET Inhibitor with Strong Binding Affinity and Long-lasting Effect in Pre-clinical Models Normant, E et al TG-1601 American Association for Cancer Research Annual Meeting (AACR) Download
February 20 2018 Umbralisib, a Novel PI3Kδ and Casein Kinase-1ε Inhibitor, in Relapsed or Refractory Chronic Lymphocytic Leukaemia and Lymphoma: an Open-label, Phase 1, Dose-escalation, First-in-human Study Burris H, et al. umbralisib (TGR-1202) THE LANCET Oncology Download
February 01 2018 6 Month Results of a Phase 2a Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Relapsing Multiple Sclerosis Fox E, et al. ublituximab (TG-1101) Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Download
December 11 2017 KI Intolerance Study: A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib (TGR-1202) in Patients with Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant to Prior BTK or PI3K Delta Inhibitor Therapy Mato A, et al. umbralisib (TGR-1202) American Society of Hematology Annual Meeting (ASH) Download
December 11 2017 An Integrated Safety Analysis of the Next Generation PI3K Delta Inhibitor Umbralisib (TGR-1202) in Patients with Relapsed/Refractory Lymphoid Malignancies Davids M, et al. umbralisib (TGR-1202) American Society of Hematology Annual Meeting (ASH) Download
December 11 2017 PI3K-Delta Inhibitors Induce Primary Monocyte Cytotoxicity but Do Not Alter Monocyte Differentiation Friedman, D et al umbralisib (TGR-1202) American Society of Hematology Annual Meeting (ASH) Download
December 10 2017 Phase I/II Study of Pembrolizumab in Combination with Ublituximab (TG-1101) and Umbralisib (TGR-1202) in Patients with Relapsed/Refractory CLL Mato A, et al. umbralisib (TGR-1202), ublituximab (TG-1101) American Society of Hematology Annual Meeting (ASH) Download
December 10 2017 Umbralisib/TGR-1202 as a Novel Dual PI3K/CK1 Inhibitor Has a Unique Therapeutic Role in Silencing Oncogenes in Aggressive Lymphomas O'Connor, et al. umbralisib (TGR-1202) American Society of Hematology Annual Meeting (ASH) Download
December 10 2017 Differential Regulation of T Cells By PI3K Delta Inhibitors in a CLL Murine Model Maharaj, et al. umbralisib (TGR-1202) American Society of Hematology Annual Meeting (ASH) Download
October 27 2017 Placebo controlled, phase 2a multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS): 6 months analysis of B cell subsets Lovett-Racke A, Fox E, et al. ublituximab (TG-1101) European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Download
October 26 2017 Patient characteristics, safety, and preliminary results of a placebo controlled, phase 2a multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis Fox E, et al. ublituximab (TG-1101) European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Download
October 26 2017 Preliminary results of phase 2 multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS) demonstrates rapid Gd-enhancing lesions decrease Inglese M, et al. ublituximab (TG-1101) European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Download
June 24 2017 Rapid and Robust B Cell Depletion in Preliminary Results of Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing forms of Multiple Sclerosis (RMS) Fox E, et al. ublituximab (TG-1101) 5th Congress of the European Academy of Neurology (EAN) Download
June 24 2017 Tolerability and activity of chemo-free triplet combination of umbralisib (TGR-1202), ublituximab, and ibrutinib in patients with advanced CLL and NHL Nastoupil L, et al. umbralisib (TGR-1202), ublituximab (TG-1101), umbralisib (TGR-1202), ublituximab (TG-1101) Congress of the European Hematology Association (EHA) Download
June 24 2017 Combination of TGR-1202, Ublituximab, and bendamustine is safe and highly active in patients with advanced DLBCL and follicular lymphoma Lunning M, et al. ublituximab (TG-1101) Congress of the European Hematology Association (EHA) Download
June 16 2017 Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE Phase 3 study Mato A, et al. ublituximab (TG-1101) International Congress on Malignant Lymphoma (ICML) Download
June 16 2017 Tolerability and activity of chemo-free triplet combination of umbralisib (TGR-1202), ublituximab, and ibrutinib in patients with advanced CLL and NHL Nastoupil L, et al. umbralisib (TGR-1202), ublituximab (TG-1101), umbralisib (TGR-1202), ublituximab (TG-1101) International Congress on Malignant Lymphoma (ICML) Download
June 15 2017 Combination of TGR-1202, Ublituximab, and Bendamustine is safe and highly active in patients with advanced DLBCL and Follicular Lymphoma Lunning M, et al. umbralisib (TGR-1202), ublituximab (TG-1101), umbralisib (TGR-1202), ublituximab (TG-1101) International Congress on Malignant Lymphoma (ICML) Download
June 14 2017 Updated Results of a Multicenter Phase I/IB Study of Umbralisib (TGR-1202) in Combination with Ibrutinib in Patients with Relapsed or Refractory MCL or CLL Davids M, et al. umbralisib (TGR-1202) International Congress on Malignant Lymphoma (ICML) Download
June 05 2017 Tolerability and activity of chemo-free triplet combination of TGR-1202, ublituximab, and ibrutinib in patients with advanced CLL and NHL Nastoupil L, et al. umbralisib (TGR-1202), ublituximab (TG-1101), umbralisib (TGR-1202), ublituximab (TG-1101) American Society of Clinical Oncology Annual Meeting (ASCO) Download
June 03 2017 Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE Phase 3 study Sharman J, et al. ublituximab (TG-1101) American Society of Clinical Oncology Annual Meeting (ASCO) Download
May 26 2017 Rapid and Robust B Cell Depletion in Preliminary Results of a Phase 2 Study of Ublituximab, Novel Glycoengineered Anti-CD20 Mab, RMS Patients Lovett-Racke A, Fox E et al. ublituximab (TG-1101) Annual Meeting of Consortium of MS Centers (CMSC) Download
May 15 2017 TGR-1202– A novel PI3K-delta inhibitor that differentially regulates T cells in CLL Pinilla-Ibarz, et al. umbralisib (TGR-1202) International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Download
May 15 2017 TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL: Updated Results of a Multicenter Phase I/Ib Study Davids M, et al. umbralisib (TGR-1202) International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Download
April 28 2017 Preliminary results of Phase 2 Multicenter Study of Ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of Multiple Sclerosis (RMS) demonstrates rapid and robust B cell depletion Lovett-Racke A, Fox E et al. ublituximab (TG-1101) American Academy of Neurology Annual Meeting (AAN) Download
April 04 2017 Preclinical Characterization of a Fully Human lgG1 Anti PD-L1 mab CK-301 Marasco W, Gorelik L, et al. TG-1501 American Association for Cancer Research Annual Meeting (AACR) Download
March 05 2017 KI intolerance study: A phase 2 study to assess the safety and efficacy of TGR-1202 in pts with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3K-delta inhibitor therapy Dorsey, Mato, et al. umbralisib (TGR-1202) American Society of Clinical Oncology Annual Meeting (ASCO) Download
February 21 2017 Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial Sharman, Burke et al. ublituximab (TG-1101) British Journal of Haematology (BJH) Download
December 16 2016 A phase 1/2 trial of ublituximab, a novel, glycoengineered anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab Sawas, O'Connor et al. ublituximab (TG-1101) British Journal of Haematology (BJH) Download
December 05 2016 Combination of Ublituximab, TGR-1202 and Bendamustine Demonstrates Significant Activity in Patients with Advanced DLBCL and Follicular Lymphoma. Lunning M, et al. umbralisib (TGR-1202) American Society of Hematology Annual Meeting (ASH) Download
December 05 2016 A Phase I Trial of TGR-1202, a Next Generation Once Daily PI3K Delta Inhibitor, in Combination with Brentuximab Vedotin, in Patients with Relapsed/Refractory Hodgkins Lymphoma Ramchandran et al. umbralisib (TGR-1202) American Society of Hematology Annual Meeting (ASH) Download
December 05 2016 Preliminary Results from a Phase I Dose Escalation Trial of Ruxolitinib and the PI3K Delta Inhibitor TGR-1202 in Myelofibrosis. Moyo et al. umbralisib (TGR-1202) American Society of Hematology Annual Meeting (ASH) Download
December 05 2016 TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL: Preliminary Results of a Multicenter Phase I/Ib Study. Davids M, et al. umbralisib (TGR-1202) American Society of Hematology Annual Meeting (ASH) Download
December 04 2016 Modulation of T cell Compartment in a Preclinical CLL Murine Model by a Selective PI3K delta inhibitor, TGR-1202. Maharaj, et al. umbralisib (TGR-1202) American Society of Hematology Annual Meeting (ASH) Download
December 04 2016 Silencing cMyc Translation as a Therapeutic Strategy Through Targeting PI3K Delta and CK1 Epsilon in Hematological Malignancies. Deng C, et al. umbralisib (TGR-1202) American Society of Hematology Annual Meeting (ASH) Download
October 27 2016 Silencing c-Myc Translation as a Therapeutic Strategy through Targeting PI3K Delta and CK1 Epsilon in Hematological Malignancies Deng C, O'Connor O, et al. umbralisib (TGR-1202) Blood Medical Journal - published by the American Society of Hematology (Blood) Download
September 14 2016 Open Label Safety Study of Ublituximab for the Treatment of Acute Neuromyelitis Optica Relapses Levy M, Mealy M, et al. ublituximab (TG-1101) European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Download
June 03 2016 Long-term follow-up of the PI3K delta inhibitor TGR-1202 demonstrates a differentiated safety profile and high response rates in CLL and NHL: Integrated-analysis of TGR-1202 monotherapy and combined with ublituximab. Burris H, Flinn I, et al. umbralisib (TGR-1202) American Society of Clinical Oncology Annual Meeting (ASCO) Download
June 01 2016 Long-term follow-up of PI3K delta inhibitor TGR-1202 demonstrates safety and high response rates in NHL: Integrated Analysis of TGR-1202 monotherapy and combined with ublituximab O'Connor O, et al. umbralisib (TGR-1202) Congress of the European Hematology Association (EHA) Download
June 01 2016 Long-term follow-up of the PI3k delta inhibitor TGR-1202 demonstrates a differentiated safety profile and high response rates in CLL: Integrated-analysis of TGR-1202 monotherapy and commbined with ublituximab. Mato A, et al. umbralisib (TGR-1202) Congress of the European Hematology Association (EHA) Download
June 01 2016 Preliminary Results of a Phase I/Ib Study of Ibrutinib in Combination with TGR-1202 in Patients with Relapsed/Refractory CLL or MCL. Davids M, et al. umbralisib (TGR-1202) Congress of the European Hematology Association (EHA) Download
April 16 2016 Differential Regulation of Human T cells by TGR-1202, A Novel PI3K-delta Inhibitor. Pinilla-Ibarz, et al. umbralisib (TGR-1202) American Association for Cancer Research Annual Meeting (AACR) Download
December 08 2015 Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib is Highly Active in Patients with Relapsed and/or Refractory Mantle Cell Lymphoma: Results of a Phase II Trial. Sharman J, et al. ublituximab (TG-1101) American Society of Hematology Annual Meeting (ASH) Download
December 08 2015 Disruption of the mTOR-eIF4F Axis By Selectively Targeting PI3Kdelta and Proteasome Potently Inhibits Cap Dependent Translation of c-Myc in Aggressive Lymphomas. Deng C, et al. umbralisib (TGR-1202) American Society of Hematology Annual Meeting (ASH) Download
December 08 2015 A Phase I Trial of TGR-1202, a Next Generation Once Daily PI3K-Delta Inhibitor in Combination with Obinutuzumab Plus Chlorambucil, in Patients with Chronic Lymphocytic Leukemia. Mahadevan D, et al. umbralisib (TGR-1202) American Society of Hematology Annual Meeting (ASH) Download
December 08 2015 Clinical Activity and Safety Profile of TGR-1202, a Novel Once Daily PI3K- Delta Inhibitor, in Patients with CLL and B-Cell Lymphoma. O'Connor O, et al. umbralisib (TGR-1202) American Society of Hematology Annual Meeting (ASH) Download
December 05 2015 Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib is Highly Active in Patients with Relapsed and/or Refractory Mantle Cell Lymphoma: Results of a Phase II Trial. SharmanJ, et al. ublituximab (TG-1101) American Society of Hematology Annual Meeting (ASH) Download
September 09 2015 a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable& Differentiated Safety Profile as a Single Agent and in Combination with a Novel Glyocengineered anti-CD20 mAb, Ublituximab in Patients with Rel/Ref CLL. O'Brien, et al. ublituximab (TG-1101) International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Download
June 20 2015 Ublituximab + TGR-1202 Demonstrates Activity and Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL. Lunning M, et al. umbralisib (TGR-1202), ublituximab (TG-1101), umbralisib (TGR-1202), ublituximab (TG-1101) International Congress on Malignant Lymphoma (ICML) Download
June 20 2015 Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 MAB, in Combination with Ibrutinib Achieves 95% ORR in Patients with High-Risk Relapsed/Refractory CLL. Burke J, et al. ublituximab (TG-1101) International Congress on Malignant Lymphoma (ICML) Download
June 20 2015 Safety and Activity of the Chemotherapy-Free Triplet of Ublituximab, TGR-1202, and Ibrutinib is Safe and Highly Active in Relapsed B-Cell Malignancies. Nastoupil L, et al. umbralisib (TGR-1202), ublituximab (TG-1101), umbralisib (TGR-1202), ublituximab (TG-1101) International Congress on Malignant Lymphoma (ICML) Download
June 20 2015 Clinical Activity and Safety Profile of TGR-1202, a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity in Patients with CLL and B-Cell Lymphoma. O'Connor, et al. umbralisib (TGR-1202) International Congress on Malignant Lymphoma (ICML) Download
June 14 2015 Ublituximab + TGR-1202 Demonstrates Activity and Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL. Lunning M, et al. ublituximab (TG-1101) Congress of the European Hematology Association (EHA) Download
June 14 2015 Clinical Activity and Safety Profile of TGR-1202 a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity, in Patients with CLL and B-Cell Lymphoma. O'Connor, et al. umbralisib (TGR-1202) Congress of the European Hematology Association (EHA) Download
June 02 2015 Safety and Activity of the Chemotherapy-free Triplet of Ublituximab, TGR-1202 and ibrutinib in Relapsed B-cell Malignancies. Fowler N, O'Brien S, et al. ublituximab (TG-1101) American Society of Clinical Oncology Annual Meeting (ASCO) Download
June 02 2015 Ubliuximab +TGR-1202 Demonstrates Activity and Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL. Lunning M, O'Brien S, et al. umbralisib (TGR-1202), ublituximab (TG-1101), umbralisib (TGR-1202), ublituximab (TG-1101) American Society of Clinical Oncology Annual Meeting (ASCO) Download
June 02 2015 Clinical Activity and Safety Profile of TGR-1202, a Novel Once Daily Pi3k Delta Inhibitor, in Patients with CLL and B-Cell Lymphoma. Burris H, Flinn I, et al. umbralisib (TGR-1202) American Society of Clinical Oncology Annual Meeting (ASCO) Download
April 18 2015 IRAK4 inhibitors display synergistic activity when combined with BTK or PI3K inhibitors in B-cell lymphomas. Vajda E, Marschke K, et al. IRAK4 American Association for Cancer Research Annual Meeting (AACR) Download
March 08 2015 Ublituximab + TGR-1202 Demonstrates Activity and a Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL: Phase I Results. Lunning M, et al. umbralisib (TGR-1202), ublituximab (TG-1101), umbralisib (TGR-1202), ublituximab (TG-1101) American Society of Hematology Annual Meeting (ASH) Download
December 09 2014 Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Combination with TGR-1202, a Next Generation Once Daily PI3K Delta Inhibitor, Demonstrate Activity in Heavily Pre-Treated and High-Risk Chronic Lymphocytic Leukemia (CLL) and B-Cell Lymphoma. Lunning M, O'Brien S, et al. umbralisib (TGR-1202), ublituximab (TG-1101), umbralisib (TGR-1202), ublituximab (TG-1101) American Society of Hematology Annual Meeting (ASH) Download
December 09 2014 Ublituximab (TG-1101) a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib is Highly Active in Patients with Relapsed and/or Refractory CLL and MCL: Results of a Phase II Trial. Sharman J, Greenwald D, et al. ublituximab (TG-1101) American Society of Hematology Annual Meeting (ASH) Download
December 09 2014 TGR-1202, a Novel Once Daily Pi3K Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity, in Patients with Chronic Lymphocytic Leukemia and B-Cell Lymphoma. Burris H, Flinn I, et al. umbralisib (TGR-1202) American Society of Hematology Annual Meeting (ASH) Download
December 09 2014 Complementary Targeting of PI3K and the Proteasome Causes Potent Inhibition of mTORC1 and NF-kappaB in Models of B- and T-Cell Lymphoma. Deng C, O'Connor O, et al. umbralisib (TGR-1202) American Society of Hematology Annual Meeting (ASH) Download
December 09 2014 The PI3K-delta Inhibitor TGR-1202 in Combination with Brentuximab Vedotin (SGN-35) Synergistically Inhibits Tubulin Polymerization and Exerts Potent Antitumor Effects in NOD/SCID Mice with Hodgkin Lymphoma Cell Line Xenografts. Locatelli, et al. umbralisib (TGR-1202) American Society of Hematology Annual Meeting (ASH) Download
July 21 2014 A Phase I Trial of Ublituximab, A Novel Glycoengineered Anti-CD20 mAb, In Combination With TGR-1202, A Next Generation PI3K Delta Inhibitor, In Patients With Chronic Lymphocytic Leukemia And Non-Hodgkin’s Lymphoma. Lunning M, O'Brien S, et al. ublituximab (TG-1101) Pan Pacific Lymphoma Conference (PPLC) Download
June 13 2014 Ublituximab (TG-1101), A Novel Anti-CD20 Monoclonal Antibody for Rituximab Relapsed/Refractory B-Cell Malignancies. O'Connor O, Farber C, et al. ublituximab (TG-1101) Congress of the European Hematology Association (EHA) Download
June 13 2014 Ublituximab (TG-1101), A Novel Glycoenginereed Anti-CD20 mAb, in Combination with Ibrutinib in Patients with CLL and MCL; Results of an Ongoing Phase II Trial. Sharman J, O'Connor O, et. al. ublituximab (TG-1101) Congress of the European Hematology Association (EHA) Download
June 13 2014 Activity of TGR-1202, a Novel Once-Daily Pi3K Delta Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies. Burris H, Flinn I, et al. umbralisib (TGR-1202) Congress of the European Hematology Association (EHA) Download
May 30 2014 A Phase I Trial of Ublituximab (TG-1101), a Novel Anti-CD20 Monoclonal Antibody (MAB) in B-Cell Lymphoma Patients with Prior Exposure to Rituximab. Changchun D, O'Connor O, et al. ublituximab (TG-1101) American Society of Clinical Oncology Annual Meeting (ASCO) Download
May 30 2014 Activity of TGR-1202, a Novel Once-Daily Pi3K Delta Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies. Burris H, Flinn I, et al. umbralisib (TGR-1202) American Society of Clinical Oncology Annual Meeting (ASCO) Download
April 09 2014 The PI3K Delta Inhibitor TGR-1202 Induces Cytotoxicity and Inhibits Phosphorylation of AKT in 17p Deleted and Non-17p Deleted CLL Cells in Vitro. Friedman D, Lanasa M, et al. umbralisib (TGR-1202) American Association for Cancer Research Annual Meeting (AACR) Download
April 09 2014 The PI3K Delta Inhibitor TGR-1202 In Combination with Brentuximab Vedotin (SGN-35) Synergistically Induces G2/M Phase Arrest and Cell Death Via Inhibition of Tubulin Polymerization in Hodgkin Lymphoma Cell Lines. Locatelli S, Carlo-Stella C, et al. umbralisib (TGR-1202) American Association for Cancer Research Annual Meeting (AACR) Download
December 10 2013 The PI3K Delta Inhibitor TGR-1202 and Proteasome Inhibitor Carfilzomib are Highly Synergistic in Killing Human B- and T-Cell Lymphoma Cells. Deng C, O'Connor O, et al. umbralisib (TGR-1202) American Society of Hematology Annual Meeting (ASH) Download
December 10 2013 The PI3K-d Inhibitor TGR-1202 in Combination with Brentuximab Vedotin (SGN-35) Synergistically Induces G2/M Phase Arrest and Cell Death Via Inhibition Of Tubulin Polymerization in Hodgkin Lymphoma Cell Lines. Locatelli S, and Carlo-Stella C, et al. umbralisib (TGR-1202) American Society of Hematology Annual Meeting (ASH) Download
December 10 2013 A Phase I Dose Escalation Study of TGR-1202, a Novel PI3K-d Inhibitor, For Patients with Relapsed or Refractory Hematologic Malignancies. Savona M, Patel M, et al. umbralisib (TGR-1202) American Society of Hematology Annual Meeting (ASH) Download
September 09 2013 The PI3k-delta inhibitor TGR-1202 induces cytotoxicity and inhibits phosphorylation of AKT in 17p deleted and non-17p deleted CLL cells in vitro. Friedman D, Lanasa M, et al. umbralisib (TGR-1202) American Association for Cancer Research Annual Meeting (AACR) Download
June 14 2013 Ublituximab (TG-1101), a Novel Anti-CD20 Monoclonal for Rituximab Relapsed/Refractory B-cell Malignancies. Changchun D, O'Connor O, et al. ublituximab (TG-1101) Congress of the European Hematology Association (EHA) Download
June 14 2013 A Novel, PI3K-Delta Specific Inhibitor in Multiple Myeloma. Vakkalanka S, Viswanadha S, et al. umbralisib (TGR-1202) Congress of the European Hematology Association (EHA) Download
June 04 2013 Final Results of a Multicenter Phase Ib Single Agent Study with the Novel Anti-CD20 Monoclonal Antibody Ublituximab (TG-1101) in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL). Cazin B, Ribrag V, et al. ublituximab (TG-1101) Congress of the European Hematology Association (EHA) Download
June 02 2013 A Phase I Dose-Escalation Trial of Ublituximab (TG-1101), a Novel Anti-CD20 Monoclonal Antibody (mAb) for Rituximab Relapsed and/or Refractory C-Cell Lymphoma Patients. Changchun D, O'Connor O, et al. ublituximab (TG-1101) American Society of Clinical Oncology Annual Meeting (ASCO) Download
June 01 2013 Novel PI3K Inhibitors Demonstrate Marked Cytotoxicity in Models of T-Cell Lymphoma, Caused Apoptosis and Were Synergistic with the Novel Anti-CD20 Monoclonal Antibody Ublituximab in Models of B-Cell Lymphoma Deng, Changchun umbralisib (TGR-1202) International Congress on Malignant Lymphoma (ICML) Download
March 10 2013 Combined Carfilzomib and Selective PI3K-d Inhibition (TGR-1202) Results in Enhanced Myeloma Cell Apoptosis. Torre C, Lonial S, et al. umbralisib (TGR-1202) American Society of Hematology Annual Meeting (ASH) Download
December 11 2012 Ublituximab (TGTX-1101), A Novel Anti-CD20 Monoclonal Antibody (mAb), Demonstrates Activity in Rituximab-sensitive and Rituximab–resistant B Non-Hodgkin Lymphoma (B-NHL) Pre-clinical In Vitro and In Vivo Models. Barth M, Czuczman M, et al. ublituximab (TG-1101) American Society of Hematology Annual Meeting (ASH) Download
December 11 2012 Ublituximab (TGTX-1101), a Novel, Third-Generation Anti-CD20 Antibody Demonstrates Enhanced Antitumor Activity Compared to Rituximab in Primary CNS and Intraocular Lymphoma Murine Models. Donnou S, Fisson S, et al. ublituximab (TG-1101) American Society of Hematology Annual Meeting (ASH) Download
December 11 2012 Ublituximab, an Optimized Anti-CD20 Monoclonal Antibody, Demonstrates Greater NK-Mediated ADCC Than Rituximab in Waldenstrom’s Macroglobulinemia Patients Supporting a Therapeutic Strategy with Ublituximab. Le Garff-Tavernier M, Leblond V, et al. ublituximab (TG-1101) American Society of Hematology Annual Meeting (ASH) Download
December 11 2012 TGR-1202 Suppresses AML and ALL Cells Via Selective Inhibition of PI3K-delta Kinase. Savona M, Vakkalanka S, et al. umbralisib (TGR-1202) American Society of Hematology Annual Meeting (ASH) Download
December 11 2012 Comparison of the PI3K-delta Inhibitors TGR1202 and GS-1101 in Inducing Cytotoxicity and Inhibiting Phosphorylation of Akt in CLL Cells in Vitro. Friedman D, Lanasa M, Weinberg B, et al. umbralisib (TGR-1202) American Society of Hematology Annual Meeting (ASH) Download
December 11 2012 Novel PI3K Inhibitors Demonstrate Marked Cytotoxicity in Models of T-Cell Lymphoma, Caused Apoptosis and Were Synergistic with the Novel Anti-CD20 Monoclonal Antibody Ublituximab in Models of B-Cell Lymphoma Changchun D, O'Connor O, et al. umbralisib (TGR-1202) American Society of Hematology Annual Meeting (ASH) Download
April 04 2012 Inhibition of PI3Kd kinase by a selective small molecule inhibitor suppresses B-cell proliferation and leukemic cell growth. Vakkalanka S, Viswanadha S, et al. umbralisib (TGR-1202) American Association for Cancer Research Annual Meeting (AACR) Download
December 13 2011 Comparison of Cell Lysis Mediated by LFB-R603 with That Mediated by Ofatumumab Against Cells Expressing Low Levels of CD20. Bellon A, Salcedo M, et al. ublituximab (TG-1101) American Society of Hematology Annual Meeting (ASH) Download
December 13 2011 Multicentre Phase I Study with an 8-Dose Regimen of Single Agent Anti-CD20 Monoclonal Antibody LFB-R603 in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL). Cazin B, Coiffier B, Cartron G, et al. ublituximab (TG-1101) American Society of Hematology Annual Meeting (ASH) Download
December 13 2011 TG20, a Transgenically-Derived Anti-CD20 Monoclonal Antibody, Exhibits Enhanced Cytotoxicity Against Cells with Low Levels of CD20. Echelard Y, Meade HM, et al. ublituximab (TG-1101) American Society of Hematology Annual Meeting (ASH) Download
December 13 2011 LFB-R603, a Third-Generation Monoclonal Anti-CD20 Antibody, Displays Additive Antitumor Activity with Antileukemic Chemotherapeutic Agents in Mouse Xenograft Models. Tourais Esteves I, Fournès B, et al. ublituximab (TG-1101) American Society of Hematology Annual Meeting (ASH) Download
December 07 2010 A Phase I study of LFB-R603, a Novel Anti-CD20 Antibody, in Patients with Relapsed Chronic Lymphocytic Leukemia. Cartron G, Cazin B, et al. ublituximab (TG-1101) American Society of Hematology Annual Meeting (ASH) Download